Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.62 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.62 |
| ▸ | RXRA | P19793 | 2/20 | 0.61 |
| ▸ | RXRB | P28702 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805633 | 0.84 | CYP1A2 (0.68) | CYP26B1CYP26A1RXRACYP1A2HDAC2 | |
| SCHEMBL4001262 | 0.83 | CYP26B1 (0.60) | CYP26B1CYP26A1CYP1A2HDAC2HCAR2 | |
| SCHEMBL4001259 | 0.83 | CYP26B1 (0.60) | CYP26B1CYP26A1CYP1A2HDAC2HCAR2 | |
| SCHEMBL8265112 | 0.80 | IP6K1 (0.57) | RXRAHDAC2HCAR2HDAC3TNKS | |
| SCHEMBL1510115 | 0.80 | IP6K1 (0.57) | RXRAHDAC2HCAR2HDAC3TNKS | |
| SCHEMBL4519154 | 0.79 | FFAR1 (0.66) | CYP26B1CYP26A1CYP1A2HDAC2HCAR2 | |
| SCHEMBL4519151 | 0.79 | FFAR1 (0.66) | CYP26B1CYP26A1CYP1A2HDAC2HCAR2 | |
| SCHEMBL4001354 | 0.79 | CYP1A2 (0.75) | CYP26B1CYP26A1RXRACYP1A2HDAC2 | |
| SCHEMBL846833 | 0.79 | CYP1A2 (0.75) | CYP26B1CYP26A1RXRACYP1A2HDAC2 | |
| SCHEMBL818742 | 0.79 | CYP1A2 (0.75) | CYP26B1CYP26A1RXRACYP1A2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP26B1 10/4885CYP26A1 15/4885RXRA 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.